Parvin Asset Management’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
Parvin Asset Management's IBRX Position: Q3 2026 in Review
Parvin Asset Management increased its ImmunityBio (IBRX) stake by 31% in Q3 2026, buying an estimated $100K and bringing the position to 52,500 shares worth $496K. The position accounts for 0.37% of the portfolio, ranked #81.
Parvin Asset Management first reported a position in IBRX in Q1 2026 and has held it in 3 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- Parvin Asset Management held 52,500 shares of ImmunityBio worth $496K as of Q3 2026.
- Parvin Asset Management bought 12,500 ImmunityBio shares in Q3 2026, an estimated $100K.
- ImmunityBio made up 0.37% of Parvin Asset Management's portfolio in Q3 2026, its #81 holding.
- Parvin Asset Management first reported a position in ImmunityBio in Q1 2026 and has held it in 3 quarters since.
- 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on Parvin Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.